Research programme: DNA vaccines - Greffex
Alternative Names: Avian influenza vaccine - Greffex; Aznthrax vaccine - Greffex; Dengue vaccine - Greffex; Ebola virus vaccine - Greffex; GREANX; GREDEN/V1-4; GREFLU/CAL; GREFLU/VIE; GreVac™ vaccines; GREVAX; H1N1 vaccine - Greffex; H7N9 vaccine - Greffex; HIV vaccine - Greffex; MERS-CoV vaccine - Greffex; Middle east respiratory syndrom coronavirus vaccine - Greffex; Plague vaccine - Greffex; Tuberculosis vaccine - Greffex; Universal influenza vaccine - GreffexLatest Information Update: 28 Sep 2023
At a glance
- Originator Greffex Inc
- Class Anthrax vaccines; Bacterial vaccines; Dengue vaccines; DNA vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza virus vaccines; Lyme disease vaccines; Plague vaccines; Tuberculosis vaccines; Viral vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Lyme disease; Middle East respiratory syndrome coronavirus; Zika virus infection
- No development reported Anthrax; Coronavirus infections; Dengue; Ebola virus infections; HIV infections; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype; Influenza virus infections; Plague; Tuberculosis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)
Development Overview
Introduction
DNA vaccines are being developed by Greffex for a variety of indications. The vaccines which are based on the company's GREVAX™ Universal Platform and GreVac™ Plug-And-Play technology are designed as small synthetic nanoparticles of genes packaged in adenoviral shells that can be modified to deliver genetic payloads wherever most beneficial. The vaccines target cells that kick start the immune system and do not need chemical adjuvants. Preclinical development of candidates for anthrax, coronavirus infections, dengue, influenza A virus H1N1 subtype, influenza A virus H5N1 subtype, influenza A virus H7N9 subtype is ongoing in USA. Early research of candidates for Ebola virus infections, HIV infections, middle east respiratory syndrome corona virus, lyme disease and zika virus infections is underway in USA.
As of August 2021, no recent reports of development was identified for early research development in plague and tuberculosis in USA (Greffex website, August 2021).
As at August 2023, no recent reports of development had been identified for preclinical development in Anthrax in USA (Parenteral), preclinical development in Dengue in USA (Parenteral), preclinical development in Influenza-A virus H7N9 subtype in USA (Parenteral), preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral), preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral), preclinical development in Influenza-virus-infections in USA (Parenteral), research development in Ebola-virus-infections in USA (Parenteral), research development in HIV-infections in USA (Parenteral).
As at September 2023, no recent reports of development had been identified for preclinical development in Coronavirus-infections in USA (Parenteral).
Company Agreements
In May 2017, Greffex and Texas A& M University System entered into a Master Research Agreement for research and development of Greffex vaccines. Financial terms of the agreement were not disclosed [1]
Key Development Milestones
As of August 2021, early research in Zika, middle east respiratory corona virus and lyme disease is underway in the US (Greffex website, August 2021).
In January 2021, results from preclinical studies for H5N1 were released by Greffex [2] .
In May 2013, Greffex announced that it had constructed the first comprehensive vaccine for H7N9 avian influenza, using its GREVAX™ technology [3] .
Greffex is carrying out preclinical development of vaccines for anthrax (GREANX™, in collaboration with the US Army Medical Research Institute for Infectious Diseases), dengue (GREDEN/V1-4™, in collaboration with the National Institute of Allergy and Infectious Diseases), influenza A H5N1 (GREFLU/VIE™) and influenza A H1N1 (GREFLU/CAL™). The company is also developing a universal influenza vaccine.
Greffex is also applying its GREVAX™ technology to develop vaccines for ebola virus infections, HIV infections, plague and tuberculosis. Early research in these indications is underway.
Financing information
In September 2019, Greffex got a contract of up to $US18.9 million with the National Institute of Health’s National Institute for Allergy and Infectious Diseases, to develop and exploit its GreVacTM Plug-And-Play technology for the production of vaccine candidates for biodefense and infectious diseases [4] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class Anthrax vaccines, Bacterial vaccines, Dengue vaccines, DNA vaccines, Influenza A virus H1N1 vaccines, Influenza A virus H5N1 vaccines, Influenza virus vaccines, Lyme disease vaccines, Plague vaccines, Tuberculosis vaccines, Viral vaccines, Zika virus vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07A-C (Anthrax vaccines)
J07A-K (Plague vaccines)
J07A-N (Tuberculosis vaccines)
J07B-B (Influenza vaccines)
J07B-X (Other viral vaccines)
-
EPhMRA code
J7A9 (Other specified single component)
J7E1 (Influenza vaccines)
Table of Contents
Development Status
Summary Table
Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
---|---|---|---|---|---|---|---|
Anthrax | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Coronavirus infections | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Sep 2023 |
Dengue | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Ebola virus infections | - | - | No development reported (Research) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
HIV infections | - | - | No development reported (Research) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Influenza A virus H1N1 subtype | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Influenza A virus H5N1 subtype | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Influenza A virus H7N9 subtype | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Influenza virus infections | - | - | No development reported (Preclinical) | USA | Parenteral / unspecified | Greffex Inc | 28 Aug 2023 |
Lyme disease | - | - | Research | USA | Parenteral / unspecified | Greffex Inc | 30 Aug 2021 |
Middle East respiratory syndrome coronavirus | - | - | Research | USA | Parenteral / unspecified | Greffex Inc | 30 Aug 2021 |
Plague | - | - | No development reported (Research) | USA | Parenteral / unspecified | Greffex Inc | 30 Aug 2021 |
Tuberculosis | - | - | No development reported (Research) | USA | Parenteral / unspecified | Greffex Inc | 30 Aug 2021 |
Zika virus infection | - | - | Research | USA | Parenteral / unspecified | Greffex Inc | 30 Aug 2021 |
Commercial Information
Involved Organisations
Organisation | Involvement | Countries |
---|---|---|
Greffex Inc | Originator | USA |
Greffex Inc | Owner | USA |
National Institutes of Health | Funder | |
Texas A&M University | Collaborator | USA |
National Institute of Allergy and Infectious Diseases | Collaborator | USA |
Brand Names
Brand Name | Organisations | Indications | Countries |
---|---|---|---|
GREANX | Greffex Inc | Anthrax | USA |
GREDEN/V1-4 | Greffex Inc | Dengue | USA |
GREFLU/CAL | Greffex Inc | Influenza A virus H1N1 subtype | USA |
GREFLU/VIE | Greffex Inc | Influenza A virus H5N1 subtype | USA |
GREVAX | Greffex Inc | Influenza virus infections | USA |
Scientific Summary
Pharmacodynamics
In preclinical studies, 100% of the mice that received the Greffex H5N1 vaccine survived after being challenged with a lethal dose of H5N1. Conversely, 100% of the mice that were not vaccinated died or were euthanized in less than a week for having lost excessive body weight. Mce receivingsingle dose and a low dosage also showed 100% survival. Additionally, strong T-cell and strong antibody responses were also observed [2] .
Future Events
Expected Date | Event Type | Description | Updated |
---|---|---|---|
31 Dec 2021 | Trial Update | Greffex plans clinical trials for Influenza A virus H5N1 subtype (Parenteral) in 2021 (Greffex Pipeline, August 2021) | 30 Aug 2021 |
Development History
Event Date | Update Type | Comment |
---|---|---|
28 Sep 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Parenteral) Updated 28 Sep 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral) Updated 28 Aug 2023 |
28 Aug 2023 | Phase Change - No development reported | No recent reports of development identified for research development in HIV-infections in USA (Parenteral) Updated 28 Aug 2023 |
30 Aug 2021 | Active Status Review | Early research is ongoing for Ebola virus infections in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Early research is ongoing for HIV-Infections in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development is ongoing for Anthrax in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development is ongoing for Influenza-A virus H1N1 subtype in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development is ongoing for Influenza-A virus H5N1 subtype in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development is ongoing for Influenza-A virus H7N9 subtype in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development is ongoing for Dengue in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Active Status Review | Preclinical development for Influenza-virus infections is ongoing in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Phase Change | Early research in Lyme disease in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Phase Change | Early research in Middle East respiratory syndrome coronavirus in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Phase Change | Early research in Zika virus infection in USA (Parenteral) (Greffex website, August 2021) Updated 30 Aug 2021 |
30 Aug 2021 | Trial Update | Greffex plans clinical trials for Influenza A virus H5N1 subtype (Parenteral) in 2021 (Greffex Pipeline, August 2021) Updated 30 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for research development in HIV-infections in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for research development in Plague in USA (Parenteral) Updated 28 Aug 2021 |
28 Aug 2021 | Phase Change - No development reported | No recent reports of development identified for research development in Tuberculosis in USA (Parenteral) Updated 28 Aug 2021 |
29 Jan 2021 | Scientific Update | Pharmacodynamics data from preclinical studies in Influenza A virus H1N1 subtype released by Greffex [2] Updated 11 Jun 2021 |
13 Aug 2019 | Active Status Review | Early research is still ongoing for Ebola virus infections, HIV infections, Plague and Tuberculosis in USA (Parenteral) (Greffex pipeline, August 2019) Updated 13 Aug 2019 |
13 Aug 2019 | Active Status Review | Preclinical development is ongoing for Anthrax, Coronavirus infections, Dengue, Influenza A virus H1N1 subtype, Influenza A virus H5N1 subtype, Influenza A virus H7N9 subtype in USA (Parenteral) (Greffex pipeline, August 2019) Updated 13 Aug 2019 |
13 Aug 2019 | Phase Change - Preclinical | Preclinical trials in Coronavirus infections in USA (Parenteral) before August 2019 (Greffex pipeline, August 2019) Updated 13 Aug 2019 |
13 Aug 2019 | Trial Update | Greffex plans clinical trials for avian influenza vaccine for Influenza virus infections (Greffex pipeline, August 2019) Updated 13 Aug 2019 |
15 May 2017 | Licensing Status | Greffex and Texas A& M University collaborate to develop DNA vaccines [1] Updated 13 Aug 2019 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Anthrax in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in HIV-infections in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Plague in USA (Parenteral) Updated 16 Jul 2016 |
16 Jul 2016 | Phase Change - No development reported | No recent reports of development identified for research development in Tuberculosis in USA (Parenteral) Updated 16 Jul 2016 |
07 May 2013 | Licensing Status | Research programme: vaccines - Greffex is available for licensing as of 07 May 2013. http://www.greffex.com Updated 08 May 2013 |
01 May 2013 | Phase Change | Early research in Ebola virus infections in USA (Parenteral) Updated 08 May 2013 |
01 May 2013 | Phase Change | Early research in HIV infections in USA (Parenteral) Updated 08 May 2013 |
01 May 2013 | Phase Change | Early research in Plague in USA (Parenteral) Updated 08 May 2013 |
01 May 2013 | Phase Change | Early research in Tuberculosis in USA (Parenteral) Updated 08 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Influenza virus infections in USA (Parenteral) Updated 08 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Anthrax in USA (Parenteral) Updated 07 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Dengue in USA (Parenteral) Updated 07 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Influenza-A virus H1N1 subtype in USA (Parenteral) Updated 07 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Influenza-A virus H5N1 subtype in USA (Parenteral) Updated 07 May 2013 |
01 May 2013 | Phase Change - Preclinical | Preclinical trials in Influenza-A virus H7N9 subtype in USA (Parenteral) Updated 07 May 2013 |
References
-
Texas A&M University System (TAMUS) and Greffex, Inc. sign agreement to collaborate on advanced process and manufacturing development.
Media Release -
Greffex Reports 100% Survival in H5N1 Avian Infuenza Pre-Clinical Trials.
Media Release -
H7N9: Greffex Beats the Clock to Build the First Comprehensive H7N9 Vaccine.
Media Release -
Greffex, Inc. Awarded NIH Contract for up to $18.9 Million to Develop a Plug-And-Play Technology Platform to Expedite the Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG